{"id":"W2947840610","doi":"10.1200/jco.2019.37.15_suppl.4005","title":"Prospective randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (CARC) <i>(</i>Alliance A021202<i>)</i>.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Clinical endpoint; Pazopanib; Internal medicine; Hazard ratio; Regorafenib; Neuroendocrine tumors; Gastroenterology; Placebo; Randomization; Progression-free survival; Randomized controlled trial; Urology; Cancer; Confidence interval; Chemotherapy; Colorectal cancer; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002786488,0.002886766,0.003230746,0.0005697001,0.000625341,0.001722022,0.001186706,0.002764117,0.01237509],"category_scores_gemma":[0.003023905,0.001182796,0.001859845,0.0004914646,0.001608714,0.001664633,0.0006101478,0.004505064,0.002404979],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001030008,"about_ca_system_score_gemma":0.001839513,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001056272,"about_ca_topic_score_gemma":0.002448542,"domain_scores_codex":[0.9990007,0.0005322315,0.00005042393,0.0002127221,0.0000580769,0.0001458358],"domain_scores_gemma":[0.9984637,0.0003911171,0.0003859703,0.0001206788,0.000101283,0.0005371858],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9865464,0.004865138,0.0002326851,0.0003000339,0.0003823484,0.00002845885,0.00002835325,0.0002057173,0.001412783,0.0001027593,0.000881693,0.005013589],"study_design_scores_gemma":[0.9694614,0.02933531,0.000324633,0.00001322026,0.0001012314,0.0000138973,0.000008006496,0.000174351,0.00009092509,0.0001091121,0.0003623963,0.000005454345],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9309223,0.008782929,0.002487501,0.003656393,0.00365944,0.0346921,0.00619079,0.0005832007,0.009025389],"genre_scores_gemma":[0.9464731,0.003366691,0.0039656,0.004827937,0.001330108,0.02680494,0.003590897,0.00007388853,0.009566812],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01237509,"threshold_uncertainty_score":0.04139876,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05478446337088199,"score_gpt":0.4539388293389862,"score_spread":0.3991543659681042,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}